Literature DB >> 171277

A testosterone-secreting, gonadotropin-responsive pure thecoma and polycystic ovarian disease.

J R Givens, R N Andersen, W L Wiser, A J Donelson, S A Coleman.   

Abstract

UNLABELLED: A 31-yr-old hirsute female with oligoamenorrhea since menarche had markedly elevated peripheral plasma testosterone (T) concentrations of 250-255 ng/100 ml (normal 20-60 ng/100 ml), which lacked a diurnal rhythm, were not suppressed by dexamethasone, were decreased by ACTH, and were massively increased to 2,530 ng/100 ml by human chorionic gonadotropin (hCG). The binding capacity of T-binding globulin (TeBG) was 0.2 mug/100 ml (normal = 1.1-3.3 mug/100 ml). Plasma delta 4-androstenedione (A) was elevated at 374-681 ng/100 ml (normal = 90-135 ng/100 ml). Plasma estrone (E1) and estradiol (E2) were normal. The endometrium was proliferative. A T-secreting tumor was suspected because the plasma T levels were higher than those observed in polycystic ovarian disease. Exploratory surgery revealed bilateral polycystic ovaries and a pure thecoma in the right ovary which was not visible on surface examination. The thecoma did not contain granulosa cells. Plasma T in the right ovarian vein, draining the tumor, was 28,200 ng/100 ml and in the left ovarian vein was 2,600 ng/100 ml. Plasma A was elevated in both ovarian veins: 11,170 ng/100 ml on the left and 8,360 ng/100 ml on the right. The thecoma contained 1.35 mug/g of T and only 0.014 mug/g and 0.007 mug/g of E2 and E1, respectively. Plasma A and T after bilateral oophorectomy and removal of the thecoma were normal at 184 ng/100 ml and 40 ng/100 ml, respectively.
CONCLUSIONS: 1) This pure thecoma produced primarily T rather than E1 OR E2 and was gonadotropin-responsive. 2) A very high plasma androgen level in a female is an important clue to the presence of a tumor. A T-secreting tumor should be ssupected when the peripheral plasma T is over 250 ng/100 ml and when plasma T increases to over 1,000 ng/100 ml following hCG stimulation. 3) Tumors cannot be classified as estrogenic or androgenic on the basis of the character of the endometrium.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 171277     DOI: 10.1210/jcem-41-5-845

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  New routes in the polycystic ovary syndrome labyrinth: a way out?

Authors:  P Moghetti; R Castello
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 2.  Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity.

Authors:  Robert L Rosenfield; Brian Bordini
Journal:  Brain Res       Date:  2010-09-25       Impact factor: 3.252

3.  Clinical features and hormonal characteristics in a case of ovarian arrhenoblastoma.

Authors:  P Tita; A Spina; G Briguglia; A Magro; D Gallo; C Finocchiaro; G Padova; V Pezzino
Journal:  J Endocrinol Invest       Date:  1996 Jul-Aug       Impact factor: 4.256

4.  Hormonal aspects of ovarian malignancy.

Authors:  J Waxman
Journal:  J R Soc Med       Date:  1984-03       Impact factor: 5.344

5.  Ovarian and peripheral steroid hormones in a case of Sertoli-Leydig cell tumor.

Authors:  D Mango; P Scirpa; M Liberati; E Menini; A Fabiano; S Mancuso
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

6.  [Gonadoblastoma and overgrowing dysgerminoma in Turner mosaicism [45, XO/46, Xi (Xq)] (author's transl)].

Authors:  D Mühlenstedt; H G Bohnet; I H Pawlowitzki; H P Schneider
Journal:  Arch Gynecol       Date:  1979-03-28

7.  Determination and properties of proteohormone receptors in malignant gynecological tumors with special reference to lactogen receptors in human breast cancer.

Authors:  H G Bohnet
Journal:  Arch Gynecol       Date:  1980
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.